Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment

Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Final OS analysis data from the OPTIMISMM trial support sequencing a pomalidomide-based regimen after lenalidomide failure in relapsed/refractory myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

A cancer care team contemplated the methods and reasoning for handling a complex case of heavily pretreated relapsed or refractory multiple myeloma.

Lenalidomide capsules and dasatinib tablets have received FDA approval through an abbreviated new drug application for various hematologic malignancies.